

Criteria Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

methamphetamine (Desoxyn[®]; and generics)

Non-formulary **methamphetamine (Desoxyn[®]; and generics)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is a Psychiatrist **-AND-**
-AND-
- Diagnosis of ADHD or ADD
-AND-

1) For patients **NOT** currently taking methamphetamine:

- Adequate trial** (7 days) of short-acting methylphenidate, **unless** allergy to an inactive ingredient or past trial and failure of a methylphenidate product (methylphenidate or dexamethylphenidate) regardless of dosage form, **-AND-**
- Adequate trial** (7 days) of short-acting amphetamine salt combo (must have at least partial response), **unless** allergy to an inactive ingredient, **-AND-**
- Adequate trial** (7 days) of short-acting dextroamphetamine (must have at least partial response), **unless** allergy to an inactive ingredient, **-AND-**
- Adequate trial** (7 days) of at least 2 long-acting amphetamine products (amphetamine salt combo, dextroamphetamine or lisdexamfetamine), **unless** allergy to an inactive ingredient

2) For patients currently taking methamphetamine:

- Adequate trial** (7 days) of short-acting amphetamine salt combo **unless** allergy to an inactive ingredient or currently taking methamphetamine (Desoxyn) with an antipsychotic or mood stabilizer (lithium or antiepileptic drug used for mood stabilization), **-AND-**
- Adequate trial** (7 days) of short-acting dextroamphetamine (must have at least partial response), **unless** allergy to an inactive ingredient or currently taking methamphetamine (Desoxyn) with an antipsychotic or mood stabilizer (lithium or antiepileptic drug used for mood stabilization), **-AND-**
- Adequate trial** (7 days) of at least 1 long-acting amphetamine product (amphetamine salt combo, dextroamphetamine or lisdexamfetamine) **unless** allergy to an inactive ingredient or currently taking methamphetamine (Desoxyn) with an antipsychotic or mood stabilizer (lithium or antiepileptic drug used for mood stabilization)
-OR-
- Dose change only: patient previously met the criteria and is already taking the drug

** Adequate trial of a short acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.